CN-acetylcysteine as an adjuvant N-acetyl cysteine for treatment of recurrent unexplained pregnancy lo

تاریخ : ۱۳۹۳/۰۶/۱۲ / تعداد بازدید : ۳۶۱

Abstract

Pregnancy could be associated with a state of oxidative stress that could initiate and propagate a cascade of changes that may lead to pregnancy wastage. This process of oxidative stress may be suppressed by the antioxidant effect of N-acetyl cysteine (NAC). The current study aimed to evaluate the effect of NAC therapy in patients diagnosed with unexplained recurrent pregnancy loss (RPL). The study was a prospective controlled study performed in the Women’s Health Centre, Assiut University, Egypt. A group of 80 patients with history of recurrent unexplained pregnancy loss were treated with NAC 0.6 g + folic acid 500 μg/day and compared with an aged-matched group of 86 patients treated with folic acid 500 μg/day alone. NAC + folic acid compared with folic acid alone caused a significantly increased rate of continuation of a living pregnancy up to and beyond 20 weeks [P < 0.002, relative risk (RR) 2.9, 95% confidence interval (CI) 1.5–5.6]. NAC + folic acid was associated with a significant increase in the tak -home baby rate as compared with folic acid alone (P < 0.047, RR 1.98, 95% CI 1.3–4.0). In conclusion, NAC is a well-tolerated drug that could be a potentially effective treatment in patients with unexplained RPL.

Click here for view full article: CN-acetylcysteine as an adjuvant N-acetyl cysteine for treatment of recurrent unexplained pregnancy loss

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

CN-acetylcysteine as an adjuvant N-acetyl cysteine for treatment of recurrent unexplained pregnancy lo

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis